Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
Rosario GarcĂa Campelo
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Felipe Cardenal
No relevant relationships to disclose
Miguel Angel Molina-Vila
No relevant relationships to disclose
Alex Martinez Marti
No relevant relationships to disclose
Juan Luis Marti-Ciriquian
No relevant relationships to disclose
Guillermo Alonso-Jaudenes Curbera
No relevant relationships to disclose
Cinta Pallares
No relevant relationships to disclose
Ramon Palmero
No relevant relationships to disclose
Maria Carmen Gonzalez-Arenas
No relevant relationships to disclose
Clara Mayo-de las Casas
No relevant relationships to disclose
Maria Sanchez-Ronco
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose